Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | KDM5C | P41229 | 2/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.36 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.36 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24997203 | 0.83 | HSP90AA1 (0.45) | LMNATDP1HDAC3HDAC1HDAC2 | |
| SCHEMBL3660629 | 0.83 | LMNA (0.63) | LMNATDP1POLBMCL1KDM4E | |
| SCHEMBL13129296 | 0.82 | LMNA (0.46) | LMNAPOLBMCL1KDM4EKDM5C | |
| SCHEMBL619312 | 0.80 | TDP1 (0.69) | TDP1KDM4EKDM5CEGLN1PHF8 | |
| SCHEMBL12934354 | 0.79 | HDAC2 (0.59) | TDP1KDM4EKDM5CEGLN1PHF8 | |
| SCHEMBL10890486 | 0.78 | — | — | |
| SCHEMBL22074237 | 0.77 | SMN1; SMN2 (0.50) | LMNAPOLBMCL1KDM4EKDM5C | |
| SCHEMBL6152745 | 0.77 | KDM4E (0.52) | LMNATDP1POLBMCL1KDM4E | |
| SCHEMBL2607890 | 0.77 | LMNA (0.46) | LMNATDP1POLBMCL1KDM4E | |
| SCHEMBL8984748 | 0.76 | TDP1 (0.64) | TDP1KDM4EKDM5CEGLN1PHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827920-B2 | Nanostructure, a biosensor including the nanostructure, and a screening method | POSTECH Research and Business Development Foundation (KR) | 2023-11-28 | — | — | US | disclosed |
| US-20230357776-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11732265-B2 | Compositions and methods for modulating complement factor B expression | IONIS PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230226201-A1 | DRUG CONJUGATE HAVING ENHANCED DRUG DELIVERY AND INTERNALIZATION EFFICIENCY | BIK THERAPEUTICS INC. (KR) | 2023-07-20 | — | — | US | disclosed |
| US-20230057718-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| US-20200048638-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2020-02-13 | — | — | US | disclosed |
| US-9340820-B2 | Compounds and methods for protease detection | QUEEN'S UNIVERSITY OF BELFAST (GB) | 2016-05-17 | — | — | US | disclosed |
| US-9085548-B2 | Pseudorotaxanes, rotaxanes and catenanes formed by metal ions templating | NATIONAL TAIWAN UNIVERSITY (TW) | 2015-07-21 | — | — | US | disclosed |
| US-20150051393-A1 | PSEUDOROTAXANES, ROTAXANES AND CATENANES FORMED BY METAL IONS TEMPLATING | NATIONAL TAIWAN UNIVERSITY (TW) | 2015-02-19 | — | — | US | disclosed |
| US-20140350242-A1 | PSEUDOROTAXANES, ROTAXANES AND CATENANES FORMED BY METAL IONS TEMPLATING | NATIONAL TAIWAN UNIVERSITY (TW) | 2014-11-27 | — | — | US | disclosed |
| US-8222239-B2 | quaternary ammonium compounds, conjugated to polymers, used as microbiocides | ALLACCEM, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20120156691-A1 | COMPOUND | QUEEN'S UNIVERSITY OF BELFAST | 2012-06-21 | — | — | US | disclosed |
| US-8173764-B2 | Solubilization and targeted delivery of drugs with self-assembling amphiphilic polymers | ALLEXCEL INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20100260743-A1 | Solubilization and Targeted Delivery of Drugs With Self-Assembling Amphiphilic Polymers | ALLEXCEL, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100239659-A1 | SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTI-CANCER AGENTS | ALLEXCEL., INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100008938-A1 | SELF ASSEMBLING AMPHIPHILIC POLYMERS AS ANTIVIRAL AGENTS | ALLEXCEL, INC. | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051393-A1 | PSEUDOROTAXANES, ROTAXANES AND CATENANES FORMED BY METAL IONS TEMPLATING | PCNA, TIMCC, SGTA | LMNA 4145/4885TDP1 4263/4885POLB 1607/4885 |
| US-20100008938-A1 | SELF ASSEMBLING AMPHIPHILIC POLYMERS AS ANTIVIRAL AGENTS | PICALM, CLTA, HAVCR2 | LMNA 2356/4885TDP1 2144/4885POLB 1162/4885 |
| US-20230226201-A1 | DRUG CONJUGATE HAVING ENHANCED DRUG DELIVERY AND INTERNALIZATION EFFICIENCY | CD44, CLTC, CLTB | LMNA 4116/4885TDP1 4111/4885POLB 4823/4885 |
| US-20100239659-A1 | SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTI-CANCER AGENTS | CD44, EPCAM, EGFR | LMNA 2786/4885TDP1 3885/4885POLB 3287/4885 |
| US-20140350242-A1 | PSEUDOROTAXANES, ROTAXANES AND CATENANES FORMED BY METAL IONS TEMPLATING | PCNA, TIMCC, SGTA | LMNA 4145/4885TDP1 4263/4885POLB 1607/4885 |
| US-20100260743-A1 | Solubilization and Targeted Delivery of Drugs With Self-Assembling Amphiphilic Polymers | CD44, ABCG2, ABCC1 | LMNA 1169/4885TDP1 2628/4885POLB 3899/4885 |
| US-20120156691-A1 | COMPOUND | DNPEP, TMPRSS15, PEPD | LMNA 2269/4885TDP1 1724/4885POLB 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.